ENSC - CIK 0001716947
The table below shows Ensysce Biosciences, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $745.48K | $1.67M | $2.21M | $3.05M | $4.15M | $1.04M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $2.01M |
| $2.93M |
| $5.28M |
| $4.40M |
| $9.09M |
| $2.46M |
| Property, plant & equipment | $117.60K | $123.64K | - | - | - | - |
| Goodwill | - | - | - | - | - | - |
| Total assets | $2.17M | $3.18M | $5.57M | $4.61M | $9.38M | $2.80M |
| Accounts payable | $1.61M | $463.46K | $1.04M | $615.29K | $1.97M | $481.97K |
| Total current liabilities | $2.84M | $2.30M | $2.51M | $1.76M | $2.80M | $1.31M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $2.84M | $2.30M | $2.51M | $1.89M | $2.80M | $1.32M |
| Retained earnings | -$143.28M | -$136.95M | -$133.22M | -$131.49M | -$125.98M | -$126.64M |
| Total equity | -$340.04K | $1.20M | $3.39M | $3.05M | $6.91M | $1.81M |